166176-45-0

Basic information

• Product Name: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZIN-3-AMINE
• Synonyms: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZIN-3-AMINE;3-AMINO-6-CHLOROIMIDAZO[1,2-B]PYRIDAZINE
• CAS NO: 166176-45-0
• Molecular Formula: C₆H₅ClN₄
• Molecular Weight: 168.59
• EINECS: 200-001-2
• Mol File: 166176-45-0.mol

Chemical Properties

• Appearance: /
• Density: 1.715 g/cm³
• Refractive Index: 1.791
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.89±0.30(Predicted)
• CAS DataBase Reference: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZIN-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZIN-3-AMINE(166176-45-0)
• EPA Substance Registry System: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZIN-3-AMINE(166176-45-0)

Safety Data

• Hazardous Substances Data: 166176-45-0(Hazardous Substances Data)

Usage

Uses

Used in Research and Scientific Study:
6-CHLORO-IMIDAZO[1,2-B]PYRIDAZIN-3-AMINE is used as a chemical compound for research and scientific study purposes. Its specialized nature and unique structure make it a valuable candidate for exploration in various scientific fields. 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZIN-3-AMINE's potential applications and properties are still being investigated, and further research is needed to fully understand its capabilities and potential uses.

InChI:InChI=1/C6H5ClN4/c7-4-1-2-6-9-3-5(8)11(6)10-4/h1-3H,8H2

Upstream product

• 18087-76-8 6-chloro-3-nitroimidazo<1,2-b>pyridazine 
• 6775-78-6 6-chloroimidazo[1,2-b]pyridazine 

Relevant articles and documents

Studies on Anti-MRSA parenteral cephalosporins I. Synthesis and antibacterial activity of 7

In order to improve the antibacterial activity of cefozopran (CZOP) against methicillin-resistant Staphylococcus aureus (MRSA), we initiated chemical modification to introduce a 2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-hydroxyimino acetyl group at the C-7 position and a 3- or 6-substituted imidazo[1,2-b]pyridazinium or 5-substituted imidazo[1,2-a]pyridinium group at the C-3' position. Although this approach successfully enhanced the anti-MRSA activity of CZOP two to eight times, a slight decrease in the activity against Gram-negative bacteria including Pseudomonas aeruginosa was involved. Among the novel derivatives, 3-(6-aminoimidazo [1,2-b]pyridazinium-1-yl) methyl-7β-[2-(5-amino -1,2,4-thiadiazol-3-yl) -2(Z)-hydroxyiminoacetamidol]-3-cephem-4-carboxylate (44a) showed an excellent balance of activity against MRSA and Gram-negative bacteria.

Synthetic studies on condensed-azole derivatives. IV. Synthesis and anti-asthmatic activities of ω-sulfamoylalkyloxyimidazo[1,2-b]pyridazines

A series of novel (imidazo[1,2-b]pyridazin-6-yl)oxyalkylsulfonamides was synthesized and evaluated for the ability to inhibit platelet activating factor (PAF)-induced bronchoconstriction in guinea pigs. The compounds bearing a gem-dialkyl or a cycloalkylidene group at the 2 position of the sulfamoylpropyloxy group in the side chain were found to have potent activity. Among them, 3-(imidazo[1,2-b]pyridazin-6-yl)oxy-2,2-dimethylpropanesulfonamide (6) showed excellent anti-asthmatic activity and the longest duration of action. The compounds bearing a methyl group at the 7 or 8 position of the imidazo[1,2-b]pyridazine ring were found to have enhanced activity. Among them, 3-(7-methylimidazo[1,2-b]pyridazin-6-yl)oxy-2,2-dimethylpropanesulfonamide (25) showed the most potent inhibitory effect, and its anti-asthmatic effect in an experimental model of allergic asthma was superior to that of theophylline. The structure-activity relationships in this series of compounds are discussed.